New Vaccine Prevents Bacterial Meningitis
|Call Nashville Med/Peds, PLLC at 615.865.4996 to schedule an appointment for your child to receive this important new vaccine.
A new vaccine—tetravalent meningococcal conjugated vaccine (MCV4)—was recently introduced for public use. This new vaccine offers a longer duration of protection than its predecessor, polysaccharide meningococcal vaccine (MPSV4) and is licensed as a single dose vaccine for people ages 11 to 55.
WHAT IS MENINGITIS?
Meningitis is a rare but debilitating infection that affects the delicate membranes covering the brain and spinal cord. The meningococcal bacteria can cause a variety of illnesses, including bacterial meningitis, blood infection and pneumonia. The disease is carried by humans and transmitted by close, face-to-face contact. Each year, between 1,400 and 2,800 cases of invasive meningococcal disease occur in the United States, with the most cases reported in the months of December and January.
Between 10 and 14 percent of all individuals who contract bacterial meningitis will die from the disease. Of those who survive the disease, up to 20 percent will suffer serious health problems such as deafness, neurological problems or limb loss.
CHILREN AND ADOLESCENTS BENEFIT MOST
The Advisory Committee on Immunization Practices at the Centers for Disease Control recommends routine vaccination for young adolescents (11-12 years old) and those entering high school who have not been immunized (around 15 years old). Experts also recommend that college freshman who live in dormitories receive immunization.
Don’t take chances. Call Nashville Med/Peds, PLLC at 615.865.4996 to schedule an immunization for your loved one today.